Impact of Metabolic Syndrome on Patient-Reported and Clinical Outcomes in Patients Undergoing Primary Total Joint Arthroplasty Authors: Andrea H. Johnson, Jane C. Brennan, Jack Parker, James H. MacDonald, Paul J. King, Justin J. Turcotte Published: 2026 ABSTRACT Introduction:Metabolic syndrome (MetS) is a group of conditions, including hypertension, obesity, diabetes mellitus, and dyslipidemia, that affects a notable portion of the adult US population. The purpose of this study was to evaluate the effect of MetS on 1-year functional outcomes (using the Patient-Reported Outcomes Measurement Information System-Physical Function [PROMIS-PF] instrument) in patients undergoing primary total hip arthroplasty (THA) or total knee arthroplasty (TKA).Methods:A retrospective review of 2181 patients (THA n = 899, TKA n = 1282) at a single institution from 2020 to 2023 was performed. All patients completed the PROMIS-PF survey at baseline and 1 year postoperatively. Univariate and multivariate analyses were performed to compare patient characteristics and outcomes between patients with MetS and non-MetS patients.Results:MetS was present in 153 (17.0%) and 317 (24.7%) of THA and TKA patients, respectively. After controlling for confounders, patients with MetS had lower rates of achieving PROMIS-PF minimal clinically important difference (MCID) at 1 year for both THA (OR, 0.58; P = 0.008) and TKA (OR, 0.74; P = 0.029). In the subgroup analysis of obese patients, MetS THA patients were less likely to achieve MCID on PROMIS-PF at 1 year (P = 0.019).Conclusions:Patients with MetS undergoing total joint arthroplasty had worse clinical outcomes and were less likely to achieve MCID on PROMIS-PF than patients without MetS. Obese THA patients with MetS were less likely to achieve MCID on PROMIS-PF. Obesity and comorbid conditions are known to increase the risk of suboptimal outcomes in patients undergoing total joint arthroplasty, and this study highlights the increased risk of patients with MetS. Total joint arthroplasty (TJA), including total knee arthroplasty (TKA) and total hip arthroplasty (THA), are among the most commonly performed orthopaedic surgeries in the United States, with procedure volumes continuing to increase.1,2 Both TKA and THA are typically successful surgeries and can substantially improve quality of life for patient suffering from end-stage osteoarthritis.3 Given that these procedures are typically performed on older adults, obesity, hypertension, and diabetes are common comorbidities in this population.4,5 Metabolic syndrome (MetS) is a medical condition that is defined as having at least three of the following comorbidities: obesity, elevated fasting glucose (or diabetes mellitus), hypertension, and dyslipidemia.6,7 Each component of MetS, along with the condition as a whole, is known to increase the risk of clinical complications for patients undergoing TJA.7-10 Although there is little debate regarding the role of MetS in increasing the risk of clinical complications following TJA, less is known about the effect that MetS has on functional outcomes following these surgeries. Obesity has been identified as a risk factor for failing to achieve the minimal clinically important difference (MCID) on both legacy outcome measures and on the Patient-Reported Outcomes Measurement Information System Physical Function (PROMIS-PF) tool.11-13 Studies on the effect of MetS on legacy outcome measures is more mixed, with some studies showing similar functional outcomes between those with MetS and those without, and some studies showing worse functional outcomes in patients with MetS.14-17 To our knowledge, no study has examined the effect of MetS on PROMIS-PF scores in patients undergoing TJA. The purpose of this study was to evaluate the effect of MetS on 30-day clinical outcomes and 1-year functional outcomes (using PROMIS-PF) on patients undergoing primary THA and TKA. We hypothesize that patients with MetS will have worse clinical and functional outcomes than patients without MetS. Materials and Methods This study was deemed exempt by the Institutional Review Board (WCG) and a waiver of informed consent was granted. Study Population A retrospective observational study of 899 patients undergoing primary unilateral THA and 1282 patients undergoing primary unilateral TKA from March 2020 to December 2023 was performed. All procedures were performed by eight board-certified orthopaedic surgeons at a single institution. All patients included in the study completed the PROMIS-PF survey at clinic visits preoperatively and at 1 year postoperatively. Metabolic Syndrome Patients were grouped by whether they had three or more of the following diagnoses based on International Classification of Diseases, 10th Revision (ICD-10) codes and body mass index (BMI): hypertension (ICD-10: I10), obesity (BMI >30 kg/m2), hyperglycemia (ICD-10: E11.x), or dyslipidemia (ICD-10: E78.1, E78.2, E78.49, E78.5). Patients with three or more diagnoses were considered to have MetS.6 Patient charts were then manually reviewed to confirm the presence or absence of MetS. Independent Variables The independent variables of interest included age, sex, BMI, race, ethnicity, American Society of Anesthesiologist score, Charlson comorbidity index (CCI) score, social vulnerability index (SVI), and hospital site. The Centers for Disease Control SVI was used to quantify socioeconomic disadvantage based on patients' zip code of residence. Overall SVI scores, as well as the four dimensions of the SVI—socioeconomic status, household characteristics, racial and ethnic minority status, and household type and transportation—were evaluated. Scores range from 0 to 1; higher scores on the SVI represent greater levels of social vulnerability. Of the 899 THA patients included in this study, 153 (17%) had MetS and 746 (83%) did not. The MetS group was older and had a higher BMI. When assessing the MetS criteria, the MetS group had increased rates of obesity (89% vs. 32%), hypertension (91% vs. 27%), hyperglycemia (46% vs. 4%), and dyslipidemia (90% vs. 24%). Of the 1282 TKA patients included in this study, 317 (25%) had MetS and 965 (75%) did not. Similarly, patients with MetS had increased rates of obesity (91% vs. 47%), hypertension (88% vs. 34%), hyperglycemia (53% vs. 4%), and dyslipidemia (86% vs. 24%). All patients with MetS had their surgery performed in a hospital setting, while 34% of THA patients without MetS and 25% of TKA patients without MetS had their surgery performed in an ambulatory setting (Table 1). Table 1Patient Demographics and ComorbiditiesTHA (n = 899)TKA (n = 1282)No MetS (n = 746)MetS (n = 153)No MetS (n = 965)MetS (n = 317)Demographics and comorbidities Age, yr65 ± 1168 ± 868 ± 969 ± 7 Sex Female435 (58.3)79 (51.6)607 (62.9)192 (60.6) Male311 (41.7)74 (48.4)358 (37.1)125 (39.4) BMI, kg/m228 ± 534 ± 430 ± 534 ± 4 Race Black117 (16)36 (24)180 (19)74 (23) White601 (81)113 (74)743 (77)229 (72) Other28 (4)4 (3)42 (4)14 (4) Ethnicity Hispanic or Latino7 (1)3 (2)11 (1)4 (1) Not Hispanic or Latino739 (99)150 (98)954 (99)313 (99) CCI score3 ± 23 ± 23 ± 14 ± 1Social vulnerability Overall social vulnerability0.0 ± 0.20.3 ± 0.20.3 ± 0.20.3 ± 0.2 Socioeconomic status0.3 ± 0.20.3 ± 0.20.3 ± 0.20.3 ± 0.2 Household characteristics0.4 ± 0.10.4 ± 0.10.4 ± 0.10.4 ± 0.2 Racial and ethnic minority status0.5 ± 0.20.5 ± 0.30.5 ± 0.30.5 ± 0.3 Household type and transportation0.3 ± 0.20.3 ± 0.20.3 ± 0.20.3 ± 0.2MetS components Obesity241 (32)136 (89)451 (47)287 (91) Hypertension203 (27)139 (91)332 (34)279 (88) Hyperglycemia30 (4)70 (46)41 (4)169 (53) Dyslipidemia177 (24)138 (90)235 (24)274 (86) No. of MetS criteria met1 ± 13 ± 01 ± 13 ± 0Hospital site Hospital491 (66)153 (100)721 (75)317 (100) Ambulatory surgery center255 (34)0 (0)244 (25)0 (0)BMI = body mass index, CCI = Charlson Comorbidity Index, MetS = metabolic syndrome, THA = total hip arthroplasty, TKA = total knee arthroplastyAll data presented as n (%) or mean ± SD. Patient Demographics and Comorbidities BMI = body mass index, CCI = Charlson Comorbidity Index, MetS = metabolic syndrome, THA = total hip arthroplasty, TKA = total knee arthroplasty All data presented as n (%) or mean ± SD. Several baseline characteristics differed between patients with and without MetS, including age, BMI, metabolic comorbidities, and surgical setting, all of which may influence postoperative outcomes independent of MetS status. These variables were therefore treated as potential confounders and were accounted for in adjusted analyses as clinically appropriate. Primary Functional Outcome Measures Functional outcomes were assessed using the PROMIS-PF v2.0 short form 10a survey, which was administered to patients at all clinic visits throughout the study period. PROMIS-PF scores were evaluated at baseline and at 1 year postoperatively. The primary functional outcome of the study was achievement of the Minimal Clinically Important Difference (MCID) on the PROMIS-PF at 1 year following TJA. The MCID was defined as a five-point improvement in PROMIS-PF t-scores from baseline. The five-point threshold was selected as this represents a ½ SD improvement using the anchor-based method applied to the Patient-Reported Outcomes Measurement Information System (PROMIS) population normative t-scores.18 Secondary Clinical Outcome Measures Secondary clinical outcomes included length of stay (LOS), discharge to skilled nursing facility (SNF), 30-day emergency department return, and 30-day readmission. Statistical Analysis Differences in patient demographics, comorbidities, social vulnerability, MetS criteria, hospital site, outcomes, and patient-reported outcomes between patients with and without MetS were assessed using Chi-square tests and two-sample independent t-tests. The Fisher exact test was performed when the assumptions of Chi-square were not met. Multivariate linear and logistic regression were used to assess MetS as a predictor for change in PROMIS score and achievement of MCID controlling for baseline PROMIS score, age, and CCI score for PROMIS-PF. A subgroup analysis was performed, including only obese patients. Differences in outcomes were assessed between obese patients with and without MetS. Multivariate linear and logistic regression were used to assess MetS as a predictor for change in PROMIS score and achievement of MCID in obese patients controlling for baseline PROMIS score, age, and CCI score in obese patients for PROMIS-PF. All statistical analyses were performed in R Studio (Version 1.4.1717 2009 to 2025 RStudio, PBC), and statistical significance was assessed at P < 0.05. Results When assessing clinical outcomes following THA, the MetS group had increased LOS (1 ± 1 vs. 1 ± 1 days; P < 0.001) and increased discharges to SNF (5% vs. <1%; P < 0.001). Following TKA, the MetS group had increased LOS (1 ± 1 vs. 1 ±1 days; P < 0.001) and an increased rate of 30-day readmission (3% vs. 1%; P = 0.023; Table 2). Table 2Hospital and 30-Day OutcomesTHA (n = 899)TKA (n = 1282)No MetS (n = 746)MetS (n = 153)P ValueNo MetS (n = 965)MetS (n = 317)P ValueHospital outcomes LOS, d1 ± 11 ± 1 <0.001 1 ± 11 ± 1 <0.001 Discharge to SNF3 (<1)8 (5) <0.001a 19 (2)11 (4)0.18930-d outcomes ED return38 (5)6 (4)0.68445 (5)20 (6)0.312 Readmission12 (2)4 (3)0.333a9 (1)9 (3) 0.023a ED = emergency department, LOS = length of stay, MetS = metabolic syndrome, SNF = skilled nursing facility, THA = total hip arthroplasty, TKA = total knee arthroplastyaIndicates Fisher exact test.All data presented as n (%) or mean ± SD.P < 0.05 in bold. Hospital and 30-Day Outcomes ED = emergency department, LOS = length of stay, MetS = metabolic syndrome, SNF = skilled nursing facility, THA = total hip arthroplasty, TKA = total knee arthroplasty Indicates Fisher exact test. All data presented as n (%) or mean ± SD. P < 0.05 in bold. In THA patients, the MetS group had decreased PROMIS-PF at both baseline (35 ± 6 vs. 37 ± 6; P < 0.001) and 1 year postoperatively (43 ± 9 vs. 47 ± 9; P < 0.001). Additionally, they had decreased improvement in PROMIS-PF as shown by a smaller average change from baseline to 1 year (9 ± 10 vs. 11 ± 9; P = 0.031) and decreased rates of MCID achievement at 1 year (65% vs. 74%; P = 0.027). In TKA patients, the MetS group had decreased PROMIS-PF at 1 year postoperatively compared with the no MetS group (43 ± 8 vs. 45 ± 8; P < 0.001). Similarly, they had decreased improvement in PROMIS-PF (6 ± 8 vs. 7 ± 8; P = 0.005) and decreased rates of MCID achievement at 1 year (51% vs. 59%; P = 0.019; Table 3). Table 3Patient-Reported OutcomesTHA (n = 899)TKA (n = 1282)No MetS(n = 746)MetS (n = 153)P ValueNo MetS (n = 965)MetS (n = 317)P ValuePROMIS-PF Baseline PF score37 ± 635 ± 6 <0.001 38 ± 637 ± 50.372 1-yr PF score47 ± 943 ± 9 <0.001 45 ± 843 ± 8 <0.001 Baseline to 1 yr change11 ± 99 ± 10 0.031 7 ± 86 ± 8 0.005 1-yr PF MCID551 (74)99 (65) 0.027 565 (59)161 (51) 0.019 MetS = metabolic syndrome, MCID = minimal clinically important difference, PF = physical function, PROMIS-PF = Patient-Reported Outcomes Measurement Information System Physical Function, THA = total hip arthroplasty, TKA = total knee arthroplastyP < 0.05 in bold.All data presented as n (%) or mean ± SD. Patient-Reported Outcomes MetS = metabolic syndrome, MCID = minimal clinically important difference, PF = physical function, PROMIS-PF = Patient-Reported Outcomes Measurement Information System Physical Function, THA = total hip arthroplasty, TKA = total knee arthroplasty P < 0.05 in bold. All data presented as n (%) or mean ± SD. After controlling for baseline PROMIS-PF, age, and CCI score, the MetS group was 72% less likely to achieve MCID at 1 year post-THA odds ratio (OR), 0.6; 95% confidence interval (CI), 0.4 to 0.9; P = 0.008) and was 35% less likely to achieve MCID at 1 year post-TKA (OR, 0.7; 95% CI, 0.6 to 1; P = 0.028; Table 4). Table 4Multivariate Regression: MetS as Predictor of Patient-Reported OutcomesTHATKAOdds Ratio95% CIP ValueOdds Ratio95% CIP ValuePROMIS-PF Change baseline to 1 yr−1.8−3.4 to −0.3 0.018 −1.3−2.3 to −0.3 0.009 1 yr MCID0.60.4-0.9 0.008 0.70.6-1.0 0.028 CCI = Charlson Comorbidity Index, MetS = metabolic syndrome, MCID = minimal clinically important difference, PROMIS = Patient-Reported Outcomes Measurement Information System, PROMIS-PF = Patient-Reported Outcomes Measurement Information System Physical Function, THA = total hip arthroplasty, TKA = total knee arthroplastyP < 0.05 in bold; controlling for baseline PROMIS score, age, and CCI score. Multivariate Regression: MetS as Predictor of Patient-Reported Outcomes CCI = Charlson Comorbidity Index, MetS = metabolic syndrome, MCID = minimal clinically important difference, PROMIS = Patient-Reported Outcomes Measurement Information System, PROMIS-PF = Patient-Reported Outcomes Measurement Information System Physical Function, THA = total hip arthroplasty, TKA = total knee arthroplasty P < 0.05 in bold; controlling for baseline PROMIS score, age, and CCI score. When assessing clinical outcomes in obese patients following THA, the MetS group had increased LOS (1 ± 2 vs. 1 ± 1 days; P < 0.001) and increased discharges to SNF (6% vs. <1%; P = 0.002). Similarly, in obese patients following TKA, the MetS group had increased LOS (1 ± 1 vs. 1 ±1 days; P < 0.001; Table 5). Table 5Hospital and 30-Day Outcomes in Obese PatientsTHA (n = 377)TKA (n = 738)No MetS (n = 241)MetS (n = 136)P ValueNo MetS (n = 451)MetS (n = 287)P ValueHospital outcomes LOS, d1 ± 11 ± 1 <0.001 1 ± 11 ± 1 <0.001 Discharge to SNF1 (<1)8 (6) 0.002a 12 (3)10 (4)0.67530-d outcomes ED return9 (4)6 (4)0.96122 (5)17 (6)0.653 Readmission2 (1)4 (3)0.1945 (1)7 (2)0.232aED = emergency department, LOS = length of stay, MetS = metabolic syndrome, SNF = skilled nursing facility, THA = total hip arthroplasty, TKA = total knee arthroplastyaIndicates Fisher exact test.All data presented as n (%) or mean ± SD.P < 0.05 in bold. Hospital and 30-Day Outcomes in Obese Patients ED = emergency department, LOS = length of stay, MetS = metabolic syndrome, SNF = skilled nursing facility, THA = total hip arthroplasty, TKA = total knee arthroplasty Indicates Fisher exact test. All data presented as n (%) or mean ± SD. P < 0.05 in bold. When assessing functional outcomes in just obese patients undergoing THA, the MetS group had decreased PROMIS-PF at 1 year (43 ± 9 vs. 47 ± 10; P < 0.001). Additionally, they had decreased improvement (8 ± 9 vs. 11 ± 9; P = 0.007) and decreased rates of MCID achievement (63% vs. 75%; P = 0.014). In obese patients undergoing TKA, the MetS group had decreased improvement (6 ± 8 vs. 7 ± 8; P = 0.015) in PROMIS-PF (Table 6). Table 6Patient-Reported Outcomes in Obese PatientsTHA (n = 377)TKA (n = 738)No MetS (n = 241)MetS (n = 136)P ValueNo MetS (n = 451)MetS (n = 287)P ValuePROMIS-PF Baseline PF score36 ± 635 ± 60.10537 ± 537 ± 50.104 1-yr PF score47 ± 1043 ± 9 <0.001 44 ± 843 ± 80.189 Baseline to 1 yr change11 ± 98 ± 9 0.007 7 ± 86 ± 8 0.015 1-yr PF MCID181 (75)85 (63) 0.014 253 (56)146 (51)0.189MetS = metabolic syndrome, MCID = minimal clinically important difference, PF = physical function, PROMIS-PF = Patient-Reported Outcomes Measurement Information System Physical Function, THA = total hip arthroplasty, TKA = total knee arthroplastyP < 0.05 in bold; all data presented as n (%) or mean ± SD. Patient-Reported Outcomes in Obese Patients MetS = metabolic syndrome, MCID = minimal clinically important difference, PF = physical function, PROMIS-PF = Patient-Reported Outcomes Measurement Information System Physical Function, THA = total hip arthroplasty, TKA = total knee arthroplasty P < 0.05 in bold; all data presented as n (%) or mean ± SD. In the subset of obese patients, after controlling baseline PROMIS-PF, age, and CCI score, the MetS group was 85% less likely to achieve MCID at 1 year post-THA (OR, 0.5; 95% CI, 0.3 to 0.9; P = 0.019; Table 7). Table 7Multivariate Regression: MetS as Predictor of Patient-Reported Outcomes in Obese PatientsTHATKAOdds Ratio95% CIP ValueOdds Ratio95% CIP ValuePROMIS-PF Change baseline to 1 yr−1.6−3.5 to 0.20.088−0.8−1.9 to 0.40.182 1-yr MCID0.50.3-0.9 0.019 0.90.7-1.20.476CCI = Charlson comorbidity index, MetS = metabolic syndrome, MCID = minimal clinically important difference, PROMIS = Patient-Reported Outcomes Measurement Information System, PROMIS-PF = Patient-Reported Outcomes Measurement Information System Physical Function, THA = total hip arthroplasty, TKA = total knee arthroplastyP < 0.05 in bold; controlling for baseline PROMIS score, age, and CCI score. Multivariate Regression: MetS as Predictor of Patient-Reported Outcomes in Obese Patients CCI = Charlson comorbidity index, MetS = metabolic syndrome, MCID = minimal clinically important difference, PROMIS = Patient-Reported Outcomes Measurement Information System, PROMIS-PF = Patient-Reported Outcomes Measurement Information System Physical Function, THA = total hip arthroplasty, TKA = total knee arthroplasty P < 0.05 in bold; controlling for baseline PROMIS score, age, and CCI score. Discussion In this study, patients with MetS undergoing TJA had an increased BMI and comorbidity burden than patients without MetS. THA patients with MetS were also older on average and had a longer LOS and increased discharge to skilled nursing facilities postoperatively. Patients undergoing TKA with MetS also had a longer LOS and were more likely to be readmitted to the hospital within 30 days of surgery. When considering patient-reported outcomes, both THA and TKA patients with MetS had a lower increase from baseline at 1 year and were less likely to achieve MCID on PROMIS-PF when controlling for confounding variables. When looking at patient-reported outcomes in obese patients with and without MetS, patients undergoing THA with MetS were less likely to achieve 1-year MCID on PROMIS-PF when controlling for confounding variables. A number of studies have shown that patients with preexisting MetS are at a higher risk of postoperative complications when undergoing orthopaedic surgical procedures, including TJA.8,19-22 A meta-analysis by Guofeng et al20 found that patients with MetS undergoing TJA have increased rates of cardiovascular complications, surgical site infections, and 30-day readmissions. A study by Kotzur et al7 using a large national database found that patients with MetS undergoing TJA had increased rates of most common complications, including wound complications, 30-day readmission, and nonhome discharge. Gage et al23 found an increase in surgical complications in patients with MetS undergoing TJA, although no increase in LOS. A more recent study by Shichman et al16 found that patients undergoing TKA with MetS had a longer LOS and an increased likelihood of nonhome discharge. A single-institution study of Medicare patients undergoing TJA found that patients with MetS had increased rates of surgical complications and nonhome discharge, although they did not note a higher rate of readmissions in this population.19 Overall, the results of this study are in line with previous studies, noting increased complication rates in patients with MetS. Patients undergoing THA with MetS had an increase in nonhome discharge, although the overall rate was low. Patients undergoing TKA with MetS had increased rates of 30-day readmission following surgery. Both THA and TKA patients with MetS in this study experienced a markedly longer hospital LOS than patients without MetS, which has been found in some, but not all previous studies. The impact of MetS on functional recovery following TJA is less well documented. The existing studies on patient reported outcome measure (PROMs) of patients with MetS undergoing TJA have examined a variety of legacy measures, although not PROMIS measures, and have reported mixed results. A study by Shichman et al16 of patients undergoing TKA with or without MetS found that both groups of patients had similar scores on the Knee Injury and Osteoarthritis Scale and the Veterans RAND-12 measures preoperatively and postoperatively, along with similar rates of MCID achievement on both measures at 1 year. Similarly, a study by Sorenson et al found that patients undergoing TJA with and without MetS had the same improvement in PROM scores across multiple measures (Oxford Hip Score, Oxford Knee Score, EuroQol five-dimension five-level questionnaire, University of California, Los Angeles Activity Scale and Forgotten Joint Score) as patients without MetS.17 To the contrary, Gandhi et al14 found that patients with MetS undergoing either TKA or THA had worse Western Ontario McMaster University Osteoarthritis Index scores at both baseline and 1 year, and a greater number of MetS factors was associated with worsening outcomes. Lu et al15 found that patients undergoing TKA with MetS had lower scores on both the Hospital for Special Surgery knee score and on the Short Form 36 health survey in the first year postoperatively. In this study, patients undergoing THA with MetS had lower baseline and 1-year PROMIS-PF scores along with a lower percentage of patients achieving MCID at 1 year, which held true in multivariate analysis as well. Patients undergoing TKA with MetS had a similar baseline PROMIS-PF score to patients without MetS, although patients with MetS had a lower 1-year score and were less likely to achieve MCID, which also held true on multivariate analysis. The role of obesity may be a notable confounder in identifying the true risk of MetS in patients undergoing TJA as both conditions are interlinked and have been identified as risk factors for poor clinical and functional outcomes.8,11-15,20,21,24,25 Relatively few studies to date have attempted to determine whether MetS or obesity is the larger contributor to complications and worse functional outcomes in patients undergoing TJA or other orthopaedic surgeries. A study by Edelstein et al19 found that in patients with MetS undergoing TJA, increasing BMI was associated only with nonhome discharge, but not complications or 30-day readmissions. Zalikha et al26 found that obese patients with MetS undergoing TJA had a higher risk of postoperative anemia, longer LOS, and increased likelihood of nonhome discharge than nonobese patients with MetS after adjusting for confounding variables. A study by Lovecchio et al22 of patients undergoing one- to three-level lumbar fusion found that after propensity score matching for demographic factors, comorbidities, and obesity class, patients with MetS were more likely to experience wound complications, readmission, and prolonged LOS than obese patients without MetS. In this study, the only differences between obese patients with and without MetS undergoing TKA were a longer LOS and a decreased change in PROMIS-PF score from baseline to 1 year. Obese patients undergoing THA with MetS had a number of worse outcomes including longer LOS, increased nonhome discharge, and decreased PROMIS-PF scores including 1 year score, change from baseline to 1 year and likelihood of achieving MCID which were all decreased when compared with obese patients without MetS. On multivariate analysis, obese patients with MetS were 85% less likely to achieve MCID at 1 year postoperatively. The increased risks associated with patients with MetS undergoing THA compared with TKA are in line with a study by DeMik et al that found obese patients undergoing THA were at a higher risk of complication when compared with obese patients undergoing TKA.10 This study does need to be considered in light of its limitations. It is a retrospective study from a single institution and may not be representative of the general population. There is an inherent selection bias because only patients who completed preoperative and 1-year postoperative PROMIS-PF measures were included in the study, and there are known disparities in which patients complete PROM tools.27 In addition, we relied on ICD-10 codes to identify the presence or absence of MetS, which may have miscategorized some patients who did not have the appropriate diagnosis codes. However, to minimize the potential impact of coding errors, charts were also manually reviewed to confirm MetS status. The study may also be underpowered to detect differences between groups in nonhome discharge, 30-day readmission, and 30-day emergency department return, as the rates of those complications were overall low in this study. Despite these limitations, this is a novel study looking at primarily functional outcomes in patients undergoing TJA with and without MetS and may provide valuable insights into the care of these patients. Conclusion Patients undergoing TJA with MetS had overall worse outcomes than patients without MetS. Both TKA and THA patients with MetS had longer hospital LOS, THA patients had an increased likelihood of nonhome discharge and TKA patients had an increased risk of readmission within 30 days. TJA patients with MetS also had lower 1-year PROMIS-PF scores and were less likely to achieve MCID on PROMIS-PF at 1 year postoperatively, even after controlling for confounding variables. When comparing just obese patients with and without MetS, all obese TJA patients with MetS had a longer LOS and obese THA patients had an increased rate of nonhome discharge. Obese THA patients with MetS also had decreased 1-year PROMIS-PF and were less likely to achieve MCID after controlling for confounding variables. Additional study is needed to validate these findings among a broader population.